The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer
Abstract Background Several studies describe an inverse statistical relationship between the presence of an allergy and development of cancer. However, the immunological mechanism involved in the relationship between these two degenerative diseases has not been explored. Aims The main objective of t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.2002 |
| _version_ | 1797292536180506624 |
|---|---|
| author | Espiridión Ramos‐Martinez Francisco Javier García‐Vazquez Ramcés Falfán‐Valencia Jorge Rojas‐Serrano Ana Alfaro‐Cruz Marcela Pérez‐Villaseñor Gerardo Aristi‐Urista Jesús Pérez‐Hernández Rosario López‐Vancell Andrea Velasco‐Medina Guillermo Velázquez‐Sámano |
| author_facet | Espiridión Ramos‐Martinez Francisco Javier García‐Vazquez Ramcés Falfán‐Valencia Jorge Rojas‐Serrano Ana Alfaro‐Cruz Marcela Pérez‐Villaseñor Gerardo Aristi‐Urista Jesús Pérez‐Hernández Rosario López‐Vancell Andrea Velasco‐Medina Guillermo Velázquez‐Sámano |
| author_sort | Espiridión Ramos‐Martinez |
| collection | DOAJ |
| description | Abstract Background Several studies describe an inverse statistical relationship between the presence of an allergy and development of cancer. However, the immunological mechanism involved in the relationship between these two degenerative diseases has not been explored. Aims The main objective of this study was to explore the possibility that the lymphocyte T helper (Th) 2 response, a characteristic of allergy, induces recognition of tumor antigens. Methods and results Patients with a clinical diagnosis of breast ductal carcinoma were included. Histopathological markers related to proliferation of tumor cells were determined (Her‐2‐neu, Ki‐67, estrogen receptor, and progesterone receptor). IHC was performed using IgE antibodies purified from an allergy patient and from each biopsy donor patient. Serum concentrations of cytokines representative of Th1 and Th2 inflammatory responses were determined. A total of 14 patients with a confirmed diagnosis of breast ductal carcinoma were included. IHC performed on biopsies showed a weak response when using purified IgE antibodies from an allergy patient; however, IHC using the IgE of each patient as the primary antibody showed an intense and highly specific signal. Serum concentrations of cytokines of the Th2 response, that is, IL‐4 (130.5 pg/mL (116–135 pg/mL)), IL‐5 (202 pg/mL (191–213 pg/mL)), and IL‐13 (105.5 pg/mL (98–117 pg/mL)), were significantly higher than those of the Th1 response, that is, IL‐6 (86 pg/mL (79–90 pg/mL)) and INF‐γ (93 pg/mL (79–99 pg/mL)). Conclusion Purified IgE antibodies specifically recognize tumor cells in breast ductal carcinoma. |
| first_indexed | 2024-03-07T19:57:51Z |
| format | Article |
| id | doaj.art-3402e0cd4bb14a3d83a6fc9ae80607c5 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-03-07T19:57:51Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-3402e0cd4bb14a3d83a6fc9ae80607c52024-02-28T13:54:59ZengWileyCancer Reports2573-83482024-02-0172n/an/a10.1002/cnr2.2002The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancerEspiridión Ramos‐Martinez0Francisco Javier García‐Vazquez1Ramcés Falfán‐Valencia2Jorge Rojas‐Serrano3Ana Alfaro‐Cruz4Marcela Pérez‐Villaseñor5Gerardo Aristi‐Urista6Jesús Pérez‐Hernández7Rosario López‐Vancell8Andrea Velasco‐Medina9Guillermo Velázquez‐Sámano10Unidad de Medicina Experimental, Facultad de Medicina Universidad Nacional Autónoma de México Mexico city MexicoDepartamento de Análisis Clínicos y Estudios Especiales Instituto Nacional de Pediatría, Laboratorio de Inmunogenética Molecular Mexico city MexicoHLA Laboratory Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas Mexico city MexicoUnidad de Enfermedades del Intersticio Pulmonar y Reumatología, Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosío Villegas” Mexico city MexicoPatología Quirúrgica, Servicio de Anatomía Patológica, Hospital General de México, “Dr. Eduardo Liceaga” Mexico City MexicoServicio de Anatomía Patológica. Hospital Regional de Alta Especialidad del Bajío León MexicoPatología Quirúrgica, Servicio de Anatomía Patológica, Hospital General de México, “Dr. Eduardo Liceaga” Mexico City MexicoUnidad de Medicina Experimental, Facultad de Medicina Universidad Nacional Autónoma de México Mexico city MexicoUnidad de Medicina Experimental, Facultad de Medicina Universidad Nacional Autónoma de México Mexico city MexicoServicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga” Mexico City MexicoServicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga” Mexico City MexicoAbstract Background Several studies describe an inverse statistical relationship between the presence of an allergy and development of cancer. However, the immunological mechanism involved in the relationship between these two degenerative diseases has not been explored. Aims The main objective of this study was to explore the possibility that the lymphocyte T helper (Th) 2 response, a characteristic of allergy, induces recognition of tumor antigens. Methods and results Patients with a clinical diagnosis of breast ductal carcinoma were included. Histopathological markers related to proliferation of tumor cells were determined (Her‐2‐neu, Ki‐67, estrogen receptor, and progesterone receptor). IHC was performed using IgE antibodies purified from an allergy patient and from each biopsy donor patient. Serum concentrations of cytokines representative of Th1 and Th2 inflammatory responses were determined. A total of 14 patients with a confirmed diagnosis of breast ductal carcinoma were included. IHC performed on biopsies showed a weak response when using purified IgE antibodies from an allergy patient; however, IHC using the IgE of each patient as the primary antibody showed an intense and highly specific signal. Serum concentrations of cytokines of the Th2 response, that is, IL‐4 (130.5 pg/mL (116–135 pg/mL)), IL‐5 (202 pg/mL (191–213 pg/mL)), and IL‐13 (105.5 pg/mL (98–117 pg/mL)), were significantly higher than those of the Th1 response, that is, IL‐6 (86 pg/mL (79–90 pg/mL)) and INF‐γ (93 pg/mL (79–99 pg/mL)). Conclusion Purified IgE antibodies specifically recognize tumor cells in breast ductal carcinoma.https://doi.org/10.1002/cnr2.2002breastcancerIgEinflammatory response |
| spellingShingle | Espiridión Ramos‐Martinez Francisco Javier García‐Vazquez Ramcés Falfán‐Valencia Jorge Rojas‐Serrano Ana Alfaro‐Cruz Marcela Pérez‐Villaseñor Gerardo Aristi‐Urista Jesús Pérez‐Hernández Rosario López‐Vancell Andrea Velasco‐Medina Guillermo Velázquez‐Sámano The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer Cancer Reports breast cancer IgE inflammatory response |
| title | The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer |
| title_full | The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer |
| title_fullStr | The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer |
| title_full_unstemmed | The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer |
| title_short | The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer |
| title_sort | type 2 inflammatory response favors recognition of tumor antigens by ige in breast cancer |
| topic | breast cancer IgE inflammatory response |
| url | https://doi.org/10.1002/cnr2.2002 |
| work_keys_str_mv | AT espiridionramosmartinez thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT franciscojaviergarciavazquez thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT ramcesfalfanvalencia thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT jorgerojasserrano thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT anaalfarocruz thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT marcelaperezvillasenor thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT gerardoaristiurista thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT jesusperezhernandez thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT rosariolopezvancell thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT andreavelascomedina thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT guillermovelazquezsamano thetype2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT espiridionramosmartinez type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT franciscojaviergarciavazquez type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT ramcesfalfanvalencia type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT jorgerojasserrano type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT anaalfarocruz type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT marcelaperezvillasenor type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT gerardoaristiurista type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT jesusperezhernandez type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT rosariolopezvancell type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT andreavelascomedina type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer AT guillermovelazquezsamano type2inflammatoryresponsefavorsrecognitionoftumorantigensbyigeinbreastcancer |